logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10172866 B1

PDFFull Text
Date of Patent:
Jan. 08, 2019

Filed:

Mar. 31, 2016

Substituted 2,3-dihydro-1h-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis

Applicant:

Arrien Pharmaceuticals Llc, Salt Lake City, UT (US);

Inventors:

Hariprasad Vankayalapati, Draper, UT (US);

Venkatakrishnareddy Yerramreddy, Andhra Pradesh, IN;

Assignee:

Arrien Pharmaceuticals LLC, Salt Lake City, UT (US);

Attorney:

Foley & Lardner LLP

Primary Examiner:

Rebecca L Anderson

Int. Cl.
CPC ...
C07D 295/116 (2006.01); C07D 401/10 (2006.01); C07D 295/135 (2006.01); C07D 213/50 (2006.01); C07D 211/14 (2006.01); C07D 231/12 (2006.01); C07D 277/42 (2006.01); C07D 211/38 (2006.01); C07D 211/58 (2006.01); A61K 31/5375 (2006.01); C07C 323/22 (2006.01); A61K 31/451 (2006.01); A61K 31/4545 (2006.01); A61K 31/495 (2006.01); A61K 31/496 (2006.01); A61K 31/5377 (2006.01); A61K 31/122 (2006.01); A61K 31/255 (2006.01); A61K 31/44 (2006.01); A61K 31/445 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5375 (2013.01); A61K 31/122 (2013.01); A61K 31/255 (2013.01); A61K 31/44 (2013.01); A61K 31/445 (2013.01); A61K 31/451 (2013.01); A61K 31/4545 (2013.01); A61K 31/495 (2013.01); A61K 31/496 (2013.01); A61K 31/5377 (2013.01); C07C 323/22 (2013.01); C07D 211/14 (2013.01); C07D 211/38 (2013.01); C07D 211/58 (2013.01); C07D 213/50 (2013.01); C07D 231/12 (2013.01); C07D 277/42 (2013.01); C07D 295/116 (2013.01); C07D 295/135 (2013.01); C07D 401/10 (2013.01); C07C 2602/08 (2017.05);
Abstract

The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the Retinoic acid-related orphan nuclear receptor γt (RORγt)/RORγ. The compounds of the present invention are useful for modulating RORγt)/RORγ activity and for treating diseases or conditions mediated by RORγt)/RORγ such as for example, disease states associated with immunopathology of human autoimmune diseases such as Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Inflammatory Colitis, Psoriasis, COPD, Pain, Obesity, Diabetes, Dyslipidemia, Osteoporosis, Asthma, Neurodegenerative diseases and Cancer.

Find Patent Forward Citations

Loading…